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Abstract: The aim of this study is to examine expression of Proliferating cell nuclear
antigen (PCNA) and p53 oncoprotein in gastric neuroendocrine tumors. 35 gastric neuroendocrine tumors were analyzed for first
histopathologic features and then, immunohistochemical study was done to detect labeling index of PCNA and accumulation of p53
protein by using monoclonal antibodies and
the Labeled strepavidin-biotin method. PCNA
labeling index and p53 protein expression

Department of Pathology, Cerrahpaşa Faculty
of Medicine, University of Istanbul,
Istanbul-Turkey

Introduction
Gastric neuroendocrine tumors (GNET) are recently
classified according to their degree of differentiation.
Klöppel et al (1, 2) and Rindi (3) proposed new
classification schemes. Klöppel et al’s classification deals
with all aspects of the pathology of GNET (1, 2). Rindi
classifies these tumors on the basis of their differentiation
status as: 1) well differentiated: argyrophil cell tumors,
mainly composed by enterochromaffin-like (ECL) cells or
gastrin-producing (G) cells or 2) poorly differentiated:
neuroendocrine carcinomas (NECs) (3, 4).
Incidence of GNET raised to 11-41% in recent series,
from 0.3% of all gastric tumors in the earlier
literature(1, 3-6). The remarkable increase in their
incidence is most likely related to our increased awareness
of these lesions and the widespread use of endoscopy in
gastroenterology practice (1, 3, 4).
Proliferating cell nuclear antigen (PNA) is an auxillary
protein for DNA polymerase delta that plays an important
role in DNA synthesis and is thought to be synthesized in
nuclei, particularly during the proliferative period of late
G1 and S-phases. PC10, a monoclonal antibody that can
be used on tissues that are rountinely fixed and embedded
in paraffin wax, has been found to recognize PCNA.

were compared with histopatholoic features
in statistical methods of Fisher’s exact, chi
square and logistic regression tests. No significant correlation was found between them
except PCNA score and depth of invasion. In
conclusion, our findings show that not p53
but PCNA appears to be useful in detecting
malignant potential of these tumors.
Key Words: Gastric neuroendocrine tumors,
PCNA, p53 oncoprotein.

Recently, this antigen was used to estimate the
correlation between PCNA and the malignant potential in
some neoplasms (5).
The p53 is a tumor supressor gene located on the
short arm of chromosome 17 and its functional
inactivation through mutation or allelic deletion plays an
important role in the development of many human
tumors like carcinomas of the lung, colon and breast.
Mutations in the gene often increase the stability of the
p53 protein, causing it to be detectable by
immunostaining (6, 7, 8). In gastric carcinomas, the
frequency of p53 mutations varies from 4 to 70% (812). These great variatioons are due to two different
factors: a) the detection of p53 gene alterations has been
done using different techniques; b) the series that have
been studied are often small, involving only one particular
histologic type. It is still controversial whether p53
mutations are associated with clinicopathologic features
and prognosis (8).
We therefore studied the immunohistochemical
staining of Proliferating cell nuclear antigen (PCNA) and
expression of p53 protein in gastric neuroendocrine
tumors and compared the results with histologic features
to find any association with the malignant potential.
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Material and Methods
Thirty-five gastric tumors which showed evidence of
neuroendocrine differentiation histologically were
randomly collected from the archieves of Department of
Pathology, Cerrahpaşa Medical School, University of
Istanbul, since 1985 to 1996. Tissues were fixed in
formalin and routinely processed in paraffin. Serial
sections were stained with hematoxylin and eosin for
histological evaluation and conventional histopathology
identified 26% well differentiated GNET and 74% poorly
differentiated GNET or neuroendocrine carcinomas.
Tumor analysis comprised determining the size, site, level
of infiltration.
Immunohistochemical studies were performed
according to the manufacturers instructions for
identifying NE differentiation in these tumors, by Labeled
strepavidin-biotin method with markers; Chromogranin
A, Synaptophysin, neuron-specific enolase, gastrin,
glucagon, serotonin, somatostatin DAKO.
Immunohistochemical tests used to detect p53 protein
(DO-7, DAKO) and PCNA (PC 10, DAKO) were performed
using the Labeled strepavidin-biotin method described
before (13).
Only the nuclei were stained, whereas the cytoplasm
and cell membrane remained unstained by PCNA and p53
staining. Therefore, the labeling indexes of the samples
stained with anti PCNA and accumulation of p53 were
determined by counting the number of positive nuclei per
1000 tumor cells. PCNA labeling index was calculated as
the percentage of positive nuclei. The cases were
classified into three subgroups; low score group for which
the PCNA labeling indexes were less than 30%, moderate
score group for which the PCNA labeling indexes were
between 31-60% and high score group for which the
PCNA labeling indexes were more than 61%. P53
expression was scored in all tumors as positive or
negative regadless of some variation in the intensity of
the immunostain in different positive cells.
For statistical analysis, Fisher’s exact, chi square and
logistic regression tests were used. Statistical significance
was defined as p<0.05.
Results
In 35 gastric tumors which showed histopathologic
features of GNET, the method for establishing NE
differentiation was relied on immunohistochemical
reactions.
General
neuroendocrine
antibodies;
Synaptophysin and Chromogranin A were found more
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frequent positive (87.5% and 70% respectively) than
Neuron Specific Enolase (53%).
Glucagon (87.5%) and Gastrin (47%) were the most
common antigens among specific hormones. Positivity
with serotonin was 22% and with somatostatin was
12.5%.
PCNA labeling index stayed within the range of 590%. Of the 35 cases, 10 had low, 19 had moderate and
6 had high PCNA score. Table 1 shows the relationship
between PCNA labeling index and histopathologic
features. There was only statistically significant
association found between PCNA and depth of invasion.
The mean PCNA labeling index in patients with tumors
extending to serosa and beyond serosa was significantly
higher. (p=0.0105 in Fisher’s exact test and p=0.0190 in
chi square test when low and intermediate score
compared, p=0.0040 in Fisher’s exact and p=0.0057 in
chi square tests when low and intermediate plus high
score compared). No statistically significant association
was found between PCNA and other histopathologic
characteristics.
Of the 35 cases, 12 had p53 accumulation (34%).
The number of positive cells and staining intensity varied
from one case to another. The range of positive nuclei
was 5-75%. The results of relationship of p53 expression
and histopathologic features were summarized in Table 1.
No significant difference was found between p53
accumulation and histopathologic features.
Normal gastric mucosa and areas of intestinal
metaplasia adjacent to carcinomas were completely
negative for p53 but moderate or low PCNA labeling
index was observed in glands with intestinal metaplasia
and dysplasia.
Also presence of associated lesions in the
neighbouring mucosa were compared with PCNA and p53
expression but no statistical significance was found (Table
2).
Discussion
In the earlier literature, GNET accounted for about
0.3% of all gastric tumors. However, recently, GNET
comprise 11 to 41% of all gastrointestinal
neuroendocrine tumors (NET). The remarkable increase
in their incidence is most likely related to our increased
awareness of the lesions and the widespread use of
endoscopy in gastroenterology practice. Experimental
studies on hypergastrinemia induced by lifelong
antisecretory treatment or proximal gastric resection has
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PCNA Index
Features

p53 expression

p

Low

Intermediate

High

Negative

Positive

value

Body-Fundus

4

8

2

11

3

NS

Antrum

6

10

4

12

8

NS

Transitional mucosa

0

1

0

0

1

NS

Table 1.

Correlation
between
histopathologic features and
PCNA index and p53 expression.

Location

Differentiation
Well

5

3

2

6

4

NS

Poorly

5

16

4

17

8

NS

Mixed

5

14

4

15

8

NS

Trabecular

2

1

1

3

1

NS

Pattern

Diffuse

0

2

0

1

1

NS

Insular

3

2

1

4

2

NS

0.01*

Depth of invasion
Muscularis

5

1

0

2

Serosa

4

16

4

16

8

Beyond serosa

1

2

2

3

2

Negative

8

15

6

18

11

NS

Positive

2

4

0

5

1

NS

Negative

1

6

1

6

2

NS

Positive

9

13

5

17

10

NS

Negative

6

9

5

11

9

NS

Positive

4

10

1

12

3

NS

Lymphatic invasion

Venous invasion

Lymphnode metastasis

NS: not significant
*(PCNA labeling index increased significantly when the depth of invasion increased, p=0.01
between low and intermediate score, p=0.005 between low and intermediate+high score)

been shown to result in GNET, raised concerns about a
possible tumorigenic effect of prolonged antisecretory
therapy in human subjects (3).
In 1980, WHO classification of endocrine tumors
applied the term carcinoid to all tumors of the diffuse NE
system, and subdivided carcinoids on the basis of various
silver and other granule staining techniques in i) EC cell
carcinoids; ii) gastrin cell carcinoids, and iii) other
carcinoids. The broad use of the WHO terminology,
however has proved difficult and often created confusion
among pathologists and clinicians. This is primarily due to
the fact that the wide application of progressively refined

tecniques in pathology, has revealed a great diversity
among NET. Secondly, the clinically characterized
carcinoid syndrome only relates to a certain type of
carcinoid, the EC-cell carcinoid. Thirdly, WHO
classification vaguely considers the biological behavior of
NET. For this reasons, a number of investigators,
proposed to replace the term “carcinoid” by the more
uncomitting name “NET”. This name includes the entire
NET spectrum, with the classic carcinoid at one hand and
the undifferentiated carcinoma at the other. They also
proposed a new classification of scheme that deals with all
aspects of the pathology of NET. The first principal is that
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PCNA Index
Features

p53 expression

p

Low

Intermediate

High

Negative

Positive

value

Positive

7

11

4

15

7

NS

Negative

3

8

2

8

5

NS

Table 2.

Correlation between associated
lesions in the nontumorous
mucosa and PCNA index and
p53 expression.

Chronic atrophic gastritis

Intestinal metaplasia
Positive

7

6

3

12

4

NS

Negative

3

13

3

11

8

NS

Positive

5

4

1

8

2

NS

Negative

5

15

5

15

10

NS

Endocrine cell hyperplasia

NS: not significant

Figure 1.

A gastric neuroendocrine tumor which shows mixed microscopic pattern. (HEX 200)

the tumors are distinguished according to the site of
origin. The second principal is to subdivide the neoplasms
into 1) tumors with benign behavior 2) tumors with
uncertain behavior, 3) tumors with low grade malignant
behavior 4) high grade malignant tumors. The main
criteria for this biologic categorization are histologic
differentiation, angioinvasion, direct invasion of
neighboring organs, and the presence of metastases and
size. The third principal is to incorporate the hormonal
function and various clinical associations of NET. (1, 2).
Rindi classifies these tumors on the basis of their
differentiation status as: 1) well differentiated: argyrophil
cell tumors, mainly composed by enterochromaffin-like
(ECL) cells or gastrin-producing (G) cells or 2) poorly
differentiated: neuroendocrine carcinomas (NECs) (3, 4).

634

Figure 2.

High PCNA labeling index in a poorly differentiated gastric
neuroendocrine tumor (PCNAX400)

Histologically, well differentiated NET show mostly
mixed architectural pattern of insular and trabecular
patterns. Microaciner pattern is seen in a minority. Tumor
cells are monomorphic and medium-sized with regular
shape and round nuclei. They shown no atypia and
occasional mitoses. In poorly differentiated NET, the
dominant pattern is trabeculae or diffuse sheets,
frequently with central necrosis. Cells are intermediate in
size, round to oval-shaped, with large nuclei, prominent
nucleoli, and frequent mitoses (3, 4). In our study,
histological evaluation and conventional histopathology
identified 26% well differentiated GNET and 74% poorly
differentiated GNET or neuroendocrine carcinomas.
PCNA is an auxiliary protein of DNA polymerase delta,
which plays a major role in synthesizing DNA and is

G. DOĞUSOY, S. GÖKSEL, I. PAKİŞ, H, DURAK, G. ERSOY, S. GÖÇENER

GNET. However, a significant association was found only
between depth of invasion and PCNA but not with
differentiation degree or other clinicopathologic features
and PCNA.

Figure 3.

P53 oncoprotein positivity in a poorly differentiated gastric
neuroendocrine tumor (p53X400)

thought to be expressed in the nuclei, particulary in late
G1 and S phases (8, 14). PCNA has drawn attention as
one of the parameters for cell proliferation kinetics in
recent years and cell proliferative activity was suggested
to be effective in judging the malignant potential of
various carcinomas. The relationship between PCNA and
the malignant potential of various cancer also has been
reported. Some authors suggested that PCNA labeling
index can be used as an indicator of malignant potential
(8). In this study, we used PCNA as an indicator of cell
proliferation activity in gastric neuroendocrine tumors.
Ooi observed that endocrine-differentiated cancer cells
are in a quiescent state, most likely arrested in the G0 and
G1 phase of the cell cycle and they represent terminally
differentiated cells as they do not stain for PCNA. This,
however, does not necessarily imply that cancers with
endocrine differentiation are less malignant (14). In
another study although there was a significant difference
in the incidence of PCNA immunoreactivity between NET
of the jejunum and ileum and those of the appendix, no
significat difference was observed in gastric
neuroendocrine tumors (15). PCNA labeling index was
found to be increased in gastric tumors in relation to
some histopathologic features such as lymph node
metastasis (16), depth of invasion, grade and vessel
invasion (17). Our study showed that PCNA labeling index
is not so how in fact and show high score in 23% of

Abnormalities in p53 have been demonstrated in a
wide variety of common human malignancies (9).
Variations in p53 positivity according to tumor histology
have been observed in gastric carcinomas. P53 positivity
is found higher in intestinal type compared to diffuse type
in many studies (8-10, 12, 18-20). The variations in p53
in the different types of gastric cancers indicate that their
carcinogenesis is different. This may reflect the fact that
many differentiated adenocarcinomas of the stomach are
thought to arise from areas of metaplasia that resemble
intestinal epithelium (10, 18). P53 is important in gastric
tumors of the intestinal type. This histological type has
various oncogenes in common with colon tumors. The
presence of p53 protein has been preferentially described
in advanced stages of gastric cancer (18-21) and a
significantly higher frequency of p53 positive staining
was observed in carcinomas which show cardia location
(20), necrosis (17), vessel invasion (12, 17, 22) and
lymph node metastasis (22-24) but, in many studies, no
relationship between p53 protein accumulation and
histopathologic features and prognosis are established (810, 25). In our study, we examined the expression of p53
in only gastric neuroendocrine tumors and like these
studies, we couldn’t found any significant association
between p53 protein expression and histopathologic
features. Some authors, reported that the 5 year survival
rate for patients with stomach cancers positive for p53
was significantly lower than for those with stomach
cancers negative for p53 (9, 22).
In conclusion, PCNA labeling index may be a good
prognostic indicator in patients with gastric
neuroendocrine carcinoma. P53 protein accumulation is
not rare in gastric neuroendocrine tumors and as p53
seems to play an important role in the carcinogenesis and
as its expression significantly correlates with some
prognostic indicators like depth of invasion and vascular
invasion, this oncogen appears to be useful in detecting
malinant potential of these tumors.

References
1.

Klöppel G., Heitz Pu., Capella C., Solcia
E.: Pathology and nomenclature of
human gastrointestinal neuroendocrine
(carcinoid) tumors and related lesions.
World, Surg 20: 132-141, 1996.

2.

Capella C, Heitz PU, Pöfler H, Solcia E,
Klöppel G. Resived classification of
neuroendocrine tumors of the lung,
pancreas and gut. Digestion 55 (Suppl
3): 11-23, 1994.

3.

Rindi G.: Clinicopathologic aspects of
gastric neuroendocrine tumors. Am J
Surg Pathol 19 (Suppl 1): S20-S29,
1995.

635

An Immunohistochemical Study of Gastric Neuroendocrine Tumors: Expression of Proliferating Cell Nuclear Antigen and P53 Oncoprotein

4.

Rind iG., Bordi C., Rappel S., La Rosa.,
Stolte M., Solcia E.: Gastric carcinoids
and neuroendocrine carcinomas:
pathogenesis, pathology, and behavior.
World J Surg 20: 168-172, 1996.

12.

Guesdon JL, Ternyn CKT, Avrameas S.
The use of avidin-biotin interaction in
immunoenzymatic tecniques. J.
Histochem. Cytochem. 27; 11311139, 1979.

5.

Maeda K, Chung Y, Onoda N, Kato Y,
Nitta A, Arimoto Y, Yamada N, Kondo Y,
Sowa M. Proliferating cell nuclear
antigen labeling index o f preoperative
biopsy specimens in gastric carcinoma
with special reference to prognosis.
Cancer 73; 528-533, 1994.

13.

Gabbert HE, Müller W, Schneiders A,
Meier S, Hommel G. The relationship of
p53 expression to the prognosis of 418
patients with gastric carcinoma. Cancer
76: 720-726, 1995.

6.

7.

8.

9.

10.

11.

636

Wright PA, Quirke P, Attanoos R,
Williams GT. Molecular pathology of
gastric carcinoma: Progress and
prospects. Hum Pathol 23: 848-859,
1992.
Stemmermann G, Heffelfinger SC,
Noffsinger A, Hui YZ, Miller MA,
Fenoglio-Preiser CM. The molecular
biology of esophageal and gastric
cancer
and
their
precursors:
Oncogenes, tumor suppressor genes,
and growth factors. Hum Pathol 25:
968-981, 1994.
Hurlimann J, Saraga EP. Expression of
p53 protein in gastric carcinomas.
Association with histologic type and
prognosis. Am J Pathol 18(12): 12471253, 1994.
Sasano H, Date F, Imatani A, Asaki S,
Nagura H. Double immunostaining for
c-erbB-2 and p53 in human stomach
cancer cells. Hum Pathol 24: 584589, 1993.
Fukunaga M, Monden T, Nakanishi H,
Ohue M, Fukuda K, Tomita N, Shimano
T, Mori T. Immunohistochemical study
of p53 in gastric carcinoma. Am J Clin
Pathol 101: 177-180, 1994.
Martin IG, Scott NS, Bell S, Pickles A,
Murday V, Dixon MF, Johnston D,
Quirke P. Gastric cancer is not
associated with Ki ras mutations or
abnormal p53 expression. Gut 31:
A1178, 1990.

14.

Ooi A, Hayashi H, Katsuda S, Nakanishi
I. Gastric carcinoma cells with
endocrine differentiation show no
evidence of poliferation. Hum Pathol
23: 736-741, 1992.

15.

Wang DG, Johnston CF, Buchanan KD.
Oncogene
expression
in
gastroenteropancreatic neuroendocrine
tumors. Cancer 80: 668-75, 1997.

16.

Maehara Y, Tomisaki S, Oda S, et al.
Lymph node metastasis and relation to
tumor growth potential and local
immun response in advanced gastric
cancer. Int J Cancer 74(2): 224-228,
1997.

17.

18.

Iochim E, Goussia A, Stefanou D,
Agnantis NJ. Expession of p53 protein
in
gastric
cancer:
an
immunohistochemical study with
correlation to proliferative activity.
Anticancer Res. 17(1A): 513-517,
1997.
Wu MS, Shun CT, Wang HP, Sheu JC,
Lee WJ, Wang TH, Lin JT. Genetic
alterations in gastric cancer: relation to
histological subtypes, tumor stage, and
Helicobacter
pylori
infection.
Gastroenterology 112: 1457-1465,
1997.

19.

Vollmers HP, Dammrich J, Hensel F,
Ribbert H, Meyer-Bahlburg A, UfkenGaul T, Korff M, Müller -Hermelink HK.
Differentiated expression of apoptosis
receptors on diffuse and intestinal type
stomach carcinoma. Cancer 79: 43340, 1997.

20.

Shun CT, Wu MS, Lin JT, et al.
Relationship of p53 and c-erbB-2
expression
to
histopathological
features, helicobacter pylori infection
and prognosis in gastric cancer.
Hepatogastroenterology 44(14): 604609, 1997.

21.

Ichiyoshi Y, Tomoda M, Tomisaki S, et
al. Macroscopic appearance and
biological character of gastric cancer
invading the muscularis propria.
Hepatogastroenterology 43(9): 553559, 1996.

22.

Ichiyoshi Y, Oiwa H, Tomisaki S, et al.
Overexpression of p53 is associated
with growth pattern and prognosis in
advanced
gastric
cancer.
Hepatogastroenterology 44(14): 546553, 1997.

23.

Kanai T, Konno H, Maruyama K, et al.
P53 overexpression and proliferative
activity do not correlate with lymph
node metastasis in early gastric cancer.
Eur Surg Res 29(1): 35-41, 1997.

24.

Kim JH, Uhm HD, Gong SJ, et al.
Relationship
between
p53
overexpression and gastric cancer
progression. Oncology 54(2): 166170, 1997.

25.

Gomyo Y, Ikeda M, Osaki M, Tatebe S,
Tsujitani S, Ikeguchi M, Kaibara N, Ito
H. Expression of p21 (waf1/cip1/sdi1),
but not p53 protein, is a factor in the
survival of patients with advanced
gastric carcinoma. Cancer 79: 20672072, 1997.

